Delving into the Latest Updates on Luseogliflozin Hydrate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Luseogliflozin, Luseogliflozin hydrate (JAN)

+ [3]

Target

SGLT2

Mechanism

SGLT2 inhibitors(Sodium/glucose cotransporter 2 inhibitors)

Therapeutic Areas

Endocrinology and Metabolic Disease

Active Indication

Diabetes Mellitus, Type 2

Inactive Indication-

Originator Organization

Taisho Pharmaceutical Co., Ltd.

Active Organization

Taisho Pharmaceutical Co., Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

JP (24 Mar 2014),

Diabetes Mellitus, Type 2

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC23H30O6S

InChIKeyWHSOLWOTCHFFBK-ZQGJOIPISA-N

CAS Registry898537-18-3

Several sodium-glucose cotransporter 2 (SGLT2) inhibitors are known to have beneficial effects on renal function in patients with type 2 diabetes. However, the long-term effects of luseogliflozin, an SGLT2 inhibitor, remain uncertain in real-world settings. This multicenter, open-label, prospective observational study evaluated the long-term effects of luseogliflozin on renal function in Japanese patients with type 2 diabetes. Fifty-four outpatients initiated on luseogliflozin at Fukuoka University Chikushi Hospital or associated clinics were enrolled from April 2018 to December 2019, with 46 patients included in the final analysis set. The primary outcome was the change in estimated glomerular filtration rate (eGFR) from baseline to 104 weeks, and secondary outcomes included the change in eGFR at week 52 and changes in body weight and blood and urinary parameters at 52 and 104 weeks. The mean duration of diabetes was 8.1 years. Baseline eGFR was 75.8 ± 17.4 mL/min/1.73m², and no decline in eGFR was observed from baseline to 104 weeks. Decline in eGFR was suppressed in the two groups stratified by baseline eGFR (< 60 and ≥ 60 mL/min/1.73m²). No changes were noted in urinary albumin excretion rate. Blood glucose, body weight, blood pressure, liver function, and uric acid levels showed significant improvements. There were four adverse events, but no serious adverse events closely related to luseogliflozin treatment. In type 2 diabetes patients, 2-year treatment with luseogliflozin provided beneficial metabolic effects and improved the rate of decline in eGFR, suggesting a renal protective effect.

19 Oct 2024·Cureus

Telogen Effluvium Following the Treatment of Euglycemic Diabetic Ketoacidosis in a Patient With Heavy Soft Drink Intake: A Case Report

Article

Author: Yoshino, Yuta ; Hayashi, Maho

Telogen effluvium can be triggered by physical exhaustion, drug use, and emotional stress. However, in approximately 33% of cases, the triggers are unknown. Telogen effluvium can develop two to three months after exposure to triggers and improve three to six months after trigger removal. This case report discusses a man with type 2 diabetes mellitus associated with heavy soft drink intake who developed telogen effluvium following treatment for euglycemic diabetic ketoacidosis with luseogliflozin. A 28-year-old man was hospitalized for euglycemic diabetic ketoacidosis. Two months after discharge, he experienced hair loss that persisted for three months. Physical wasting due to hyperglycemia and ketoacidosis was assumed to have triggered hair loss, resulting in rapid weight loss. Investigating the triggers associated with alopecia is crucial for diagnosing and treating telogen effluvium.

01 Sep 2024·Journal of Gastroenterology

Effects of luseogliflozin on suspected MASLD in patients with diabetes: a pooled meta-analysis of phase III clinical trials

Article

Author: Kaneko, Fumi ; Kajiyama, Hiromitsu ; Murotani, Kenta ; Toyofuku, Yuko ; Yamaguchi, Hironori ; Kawaguchi, Takumi ; Seino, Yutaka ; Obara, Hitoshi ; Uchida, Saeko

AbstractBackgroundLuseogliflozin, a sodium–glucose cotransporter 2 inhibitor, potentially exerts pleiotropic effects on the liver. However, the sufficient evidence is still lacking. We aimed to investigate the effects of luseogliflozin on hepatic steatosis, fibrosis, and cardiometabolic risk factors in diabetic patients by a pooled meta-analysis.MethodsIn this pooled meta-analysis, we enrolled diabetic patients who participated in phase III clinical trials of luseogliflozin (luseogliflozin group n = 302, placebo group n = 191). The primary outcomes were changes in fatty liver index (FLI) and Hepamet fibrosis score (HFS) after 24 weeks. The secondary outcomes were changes in cardiometabolic risk factors after 24 weeks. Statistical analysis was performed using propensity scoring analysis by the inverse probability of treatment weighting method.ResultsPrimary outcomes: Luseogliflozin significantly decreased FLI compared to placebo after 24 weeks (adjusted coefficient − 5.423, 95%CI − 8.760 to − 2.086, P = 0.0016). There was no significant difference in changes in HFS between the two groups. However, luseogliflozin significantly decreased HFS compared to placebo in diabetic patients with ALT > 30 U/L (adjusted coefficient − 0.039, 95%CI − 0.077 to − 0.001, P = 0.0438) and with FIB-4 index > 1.3 (adjusted coefficient − 0.0453, 95%CI − 0.075 to − 0.016, P = 0.0026). Secondary outcom8es: Luseogliflozin significantly decreased HbA1c level, HOMA-IR value, BMI, and uric acids level, and increased HDL cholesterol level compared to placebo.ConclusionsThis pooled meta-analysis demonstrated that 24-week treatment with luseogliflozin improved hepatic steatosis and fibrosis indexes in diabetic patients, especially those with liver injury. Furthermore, luseogliflozin improved various cardiometabolic risk factors. Thus, luseogliflozin may be useful for improving MASLD in diabetic patients.Graphical abstract

100 Deals associated with Luseogliflozin Hydrate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D10195	Luseogliflozin Hydrate	A10BH	DB12214

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	JP	Taisho Pharmaceutical Co., Ltd.	24 Mar 2014

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


JPRN-jRCTs011180019 \| JPRN-UMIN000031451 (EASD2021)	Phase 4	Diabetes Mellitus, Type 2 \| Hypertension	56	Luseogliflozin 2.5 mg/day	eirukjtkcq(gkemfvaopk) = anjihtdjea occjdntksc (sglswrunbt )	Positive	30 Sep 2021
				DPP-4i	eirukjtkcq(gkemfvaopk) = irzmrmvgwh occjdntksc (sglswrunbt ) View more
EASD2020	Not Applicable	Insulinoma	-	Luseogliflozin 0.01%	kodpyqzqnn(rgtvmzjalr) = wjcztcmott apckjszwtl (fpzdzxftoa ) View more	-	22 Sep 2020
				Luseogliflozin (Standard Chow)	iuivgkiwct(xllqjhagpk) = mefkqweifk dcuzpctkvk (zvegyusdsv )
ASN2019	Phase 3	Diabetes Mellitus, Type 2	941	Luseogliflozin 2.5 mg daily	(hrvhosqtml) = nswchvovlg rqmpeqmbxn (tkwfkvyonr )	Positive	05 Nov 2019
ISC2018	Not Applicable	Hyperglycemia	-	Luseogliflozin 2.5mg	tvbwjfoefp(jmxvjmdjdw) = vauflgenmh bgmokfwbll (japygdseln )	-	22 Jan 2018
EASD2016	Not Applicable	Insulinoma	6	Luseogliflozin	tjrqxdqkoc(lcqjcatooi) = elevated relative to Controls awykiudegk (bnmlomhbtw ) View more	Positive	13 Sep 2016
				luseogliflozin (Control group)
EASD2015	Not Applicable	Fatty Liver	16	Luseogliflozin	(iimndmomkv) = unekatrjfh bbquzbyabd (sfpjehibqz, 58.8 - 76.2) View more	Positive	17 Sep 2015
				Sitagliptin	(iimndmomkv) = bnofzajcwm bbquzbyabd (sfpjehibqz, 59.6 - 76.3) View more
JPRN-JapicCTI-111507 (EASD2013)	Not Applicable	Diabetes Mellitus, Type 2 Add-on	221	Luseogliflozin 2.5 mg	(pgchrczkwb) = Incidence of hypoglycemia with patients who received luseogliflozin for 52 weeks was 10.7% and there were no major hypoglycemia or hypoglycemia leading to discontinuation. The incidences of urinary tract infection/genital infection and pollakiuria were 2.7% and 2.8%, and every event was mild in severity. kjcauulfgl (gdduazdnys )	Positive	26 Sep 2013
JPRN-JapicCTI-111661 \| JPRN-JapicCTI-111509 (EASD2013)	Phase 3	Diabetes Mellitus, Type 2	-	Luseogliflozin 2.5 mg	(mdriynhwaj) = Frequencies of adverse events were similar across groups (Luseogliflozin 2.5mg, 59.5%; placebo, 57.0%) in Study-1 and 75.3% in Study-2. Most adverse events were mild in severity. There were no major changes in clinical laboratory tests. Luseogliflozin was well tolerated throughout both studies. mrighsaibt (pfgxucjbjp )	Positive	25 Sep 2013
JPRN-JapicCTI-111508 (EASD2013)	Phase 3	Diabetes Mellitus, Type 2 Add-on	487	Luseogliflozin 2.5 mg	ovgolmgypj(isyqcidxqp) = observed in all groups, but most of these events were mild in severity rncngzmjzo (estdphkujw ) View more	Positive	25 Sep 2013
				Luseogliflozin 5 mg